PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 368.60
Bid: 368.40
Ask: 368.80
Change: 1.20 (0.33%)
Spread: 0.40 (0.109%)
Open: 360.20
High: 369.20
Low: 360.20
Prev. Close: 367.40
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

27 Sep 2016 07:00

RNS Number : 8766K
QinetiQ Group plc
27 September 2016
 

 

QinetiQ Group plc

 

David Smith appointed as new CFO of QinetiQ

 

QinetiQ announces today that David Smith has been appointed as Chief Financial Officer (CFO). David will take up the role in the New Year and there will be a further announcement once his start date is confirmed. He succeeds David Mellors, who leaves QinetiQ on 31 December 2016 to join Cobham as Chief Financial Officer.

David Smith is currently Chief Financial Officer and a Director of Rolls Royce where he has made an important contribution to restoring confidence in the business, improving financial systems and delivering the early stages of its transformation. David was CFO of the technology group Edwards immediately prior to joining Rolls Royce; he has previously been Chief Executive Officer of Jaguar Land Rover and held a number of senior finance positions at Ford. He holds an MA in Economics from Cambridge University and an MBA from Warwick University.

Steve Wadey, QinetiQ Chief Executive Officer said:

"We are delighted that David has agreed to join QinetiQ. He has extensive executive experience in blue chip companies and I am confident that he will make a significant contribution to delivering sustainable growth at QinetiQ."

David Smith said:

"QinetiQ is a science and engineering company with unique capabilities that are particularly well matched to emerging themes in global markets. I've been struck by the ambition of its leadership team and am excited about helping QinetiQ to realise its potential."

On appointment to QinetiQ, David Smith will receive a basic annual salary of £440,000. In line with QinetiQ's approved remuneration policy, he will be eligible to participate in the Bonus Banking Plan and long-term incentive arrangements, and will receive a payment in lieu of pension contributions. He will join the QinetiQ Board of Directors and become a member of the Risk & CSR and Security Committees.

David Smith is a Non-executive Director of Motability Operations Group plc. Its shares are not publicly listed but it has debt instruments listed on the main market of the London Stock Exchange. David was previously a Director of Edwards Group Limited.

There are no other matters requiring disclosure under LR 9.6.13.

QinetiQ will issue a pre close trading update on 29 September 2016 and will report results for the half year ended 30 September 2016 on 17 November 2016.

This announcement contains inside information and the person responsible for making this announcement is Jon Messent, Company Secretary.

 

For further information, please contact:

 

Investor Relations: David Bishop, QinetiQ +44 (0)7920 108675

Media Relations: QinetiQ Press Office +44 (0)1252 393500

 

About QinetiQ:

Listed on the London Stock Exchange (LSE: QQ.L), QinetiQ is a leading science and engineering company operating primarily in the defence, security and aerospace markets. Our customers are predominantly government organisations, including defence departments, as well as international customers in other targeted sectors.

 

See www.QinetiQ.com | www.QinetiQ-blogs.com | @QinetiQ.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKQLFLQKFEBBD
Date   Source Headline
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.